Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Lipid droplets, the Holy Grail of hepatic stellate cells: In health and hepatic fibrosis

Roles of the Lipid Metabolism in Hepatic Stellate Cells Activation

Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

New Perspectives on Chinese Medicine in Treating Hepatic Fibrosis: Lipid Droplets in Hepatic Stellate Cells

Hepatic Stellate Cell: A Double-Edged Sword in the Liver

A new perspective on NAFLD: Focusing on lipid droplets

Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis

[Update on isolation and functional research of hepatic stellate cells]

Effect of Lipid on Proliferation and Activation of Rat Hepatic Stellate Cells (I)

Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis

Liver Sinusoidal Endothelial Cells in Hepatic Fibrosis

Lipid Droplet Deposition in the Regenerating Liver: A Promoter, Inhibitor, or Bystander?

Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling.

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Lipid droplets: a cellular organelle vital in cancer cells

Lipid droplet-associated hydrolase mobilizes stores of liver X receptor sterol ligands and protects against atherosclerosis

Early activation of hepatic stellate cells induces rapid initiation of retinyl ester breakdown while maintaining lecithin:retinol acyltransferase (LRAT) activity

Hormone-sensitive lipase is a retinyl ester hydrolase in human and rat quiescent hepatic stellate cells

Effects of Lipid on Low-Density and High-Density Lipoprotein Receptors in Hepatic Stellate Cell from Rat Liver